Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cediranib maleate by AstraZeneca for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Cediranib maleate is under clinical development by AstraZeneca and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Cediranib maleate by AstraZeneca for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Cediranib maleate is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Cediranib maleate by AstraZeneca for Small-Cell Lung Cancer: Likelihood of Approval
Cediranib maleate is under clinical development by AstraZeneca and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...